

## CORRECTION

---

# Correction to: Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery 5-Year Results of the Zilver PTX Randomized Trial

In the article by Dake et al, “Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery 5-Year Results of the Zilver PTX Randomized Trial,” which published online before print March 11, 2016, and appeared in the April 12, 2016 issue (*Circulation*. 2016;133:1472–1483. doi: 10.1161/CIRCULATIONAHA.115.016900), corrections are needed.

When high-resolution files were requested during production, an incorrect version of Figure 1 was mistakenly provided. Subsequently, the published version of the flow chart in Figure 1 contained incorrect numbers. The authors now provide the corrected version of Figure 1.

Additionally, the following sentence from the ‘Safety’ section is incorrect:

“The 5-year all-cause mortality rate was 13.6% (10.2% for the primary DES group and 16.9% for the PTA group,  $P=0.03$ ), and no deaths were adjudicated as procedure or device related.”

The authors regret that the numbers for the two groups were inadvertently reversed. The sentence should read:

“The 5-year all-cause mortality rate was 13.6% (16.9% for the primary DES group and 10.2% for the PTA group,  $P=0.03$ ), and no deaths were adjudicated as procedure or device related.”

These corrections have been made to the current online version of the article, which is available at <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.115.016900>.